Letter to shareholders from CLINUVEL’s CEO
April 29, 2022 01:20 ET
|
Clinuvel Pharmaceuticals Limited
LONDON, April 29, 2022 (GLOBE NEWSWIRE) -- Dear shareholders, friends, Both from a professional viewpoint and as largest private holder, I have felt the urge to share my uncensored mind on...
CLINUVEL Expands Pharmaceutical Portfolio
November 07, 2021 23:03 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Nov. 08, 2021 (GLOBE NEWSWIRE) -- CLINUVEL has expanded its pharmaceutical development portfolio with NEURACTHEL®, novel formulations of the melanocortin adrenocorticotropic...
CLINUVEL expands DNA Repair Program
March 23, 2021 20:10 ET
|
Clinuvel Pharmaceuticals Limited
SCENESSE® (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V) MELBOURNE, Australia, March 24, 2021 (GLOBE NEWSWIRE) -- CLINUVEL has expanded its clinical program to...
CLINUVEL to Trial Innovative Drug in Stroke
October 27, 2020 18:50 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 28, 2020 (GLOBE NEWSWIRE) -- The drug afamelanotide will be used for the first time in patients with acute stroke. The study will evaluate the safety and efficacy of...
First patient dosed in SCENESSE® DNA Repair Program
September 15, 2020 03:31 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment Note to editors: CLINUVEL is releasing in-depth infographics and a video...
CLINUVEL progresses innovative DNA Repair Program
September 10, 2020 03:18 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Sept. 10, 2020 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced the progression of its drug SCENESSE® (afamelanotide 16mg) to treat the disease xeroderma...
CLINUVEL Opens VALLAURIX R&D Centre In Singapore
August 31, 2020 05:35 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and SINGAPORE, Aug. 31, 2020 (GLOBE NEWSWIRE) -- The CLINUVEL Group today announced the opening of its state-of-the-art centralised Research & Development Centre in...
PRÉNUMBRA® - CLINUVEL's Second Afamelanotide Formulation
July 13, 2020 03:38 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and SINGAPORE, July 13, 2020 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS today revealed PRÉNUMBRA®, the Company’s second afamelanotide product in development. PRÉNUMBRA® is a...
SCENESSE® to be Prescribed in China
April 23, 2020 02:08 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and HANGZHOU, China, April 23, 2020 (GLOBE NEWSWIRE) -- Australian-based company CLINUVEL is launching SCENESSE® (afamelanotide 16mg) in the People’s Republic of China for the...
Innovative drug launched for rare, isolating, “light intolerance” disorder
April 16, 2020 02:53 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and MENLO PARK, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Americans living with a rare genetic disorder that forces them to choose between self-isolation in the dark, or...